New immunotherapy combinations enter the battlefield of malignant mesothelioma

Mihaela Aldea, Jose Carlos Benitez, Nathalie Chaput, Benjamin Besse

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)

    Abstract

    Chimeric antigen receptor (CAR) T cells targeting mesothelin plus pembrolizumab, and atezolizumab plus bevacizumab, have recently shown clinical efficacy in phase I trials in malignant pleural and peritoneal meso-thelioma. Despite being tested in a highly selected patient population and requiring a complex engineering that can hardly be upscaled, CAR T cells combined with pembrolizumab bring the first proof of efficacy in cold solid tumors with low genomic heterogeneity, while atezolizumab–bevacizumab offers an easy-to-use combination of antiangiogenics and immunotherapy in an orphan disease.

    Original languageEnglish
    Pages (from-to)2674-2676
    Number of pages3
    JournalCancer Discovery
    Volume11
    Issue number11
    DOIs
    Publication statusPublished - 1 Nov 2021

    Cite this